Geneos Therapeutics Presents Personalized Neoantigen-Based DNA Therapy That Sustains Anti-tumor Immunity in Brain Cancer Patients and Offers a Path to Dynamic Therapy - PR Newswire
Geneos Therapeutics presented extended follow-up (Abstract CTIM-23, SNO Annual Meeting, presented by Washington University's Tanner Johanns) on two high-grade glioma patients treated with its personalized neoantigen DNA immunotherapy (PIC). A newly diagnosed MGMT-unmethylated glioblastoma patient on the GT-20 trial (NCT04015700) received 19 doses encoding 38 neoantigens over five years and is progression-free five years post-diagnosis, with imaging findings consistent with progression at 1.7, 2.2, and 3 years largely resolving while on PIC alone. The data support the feasibility of sustained immune surveillance and a dynamic therapy model in CNS tumors — an argument for longitudinal re-sequencing and iterative vaccine updates as a differentiator for DNA-based platforms.